Inozyme Pharma IncNASDAQ:INZY
- LAST PRICE4.4900
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots4.3500/ 3
- Ask / Lots4.8400/ 2
- Open / Previous Close4.4800 / 4.4900
- Day Range
- 52 Week Range
- Volume154,188
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | INZY |
|---|---|---|
| 09:32 ET | 4058 | 4.45 |
| 09:38 ET | 100 | 4.44 |
| 09:39 ET | 100 | 4.44 |
| 09:41 ET | 100 | 4.435 |
| 09:50 ET | 400 | 4.46 |
| 09:54 ET | 718 | 4.44 |
| 10:03 ET | 300 | 4.44 |
| 10:10 ET | 200 | 4.42 |
| 10:19 ET | 400 | 4.4207 |
| 10:21 ET | 950 | 4.4391 |
| 10:28 ET | 100 | 4.43 |
| 10:30 ET | 101 | 4.421 |
| 10:32 ET | 100 | 4.43 |
| 10:35 ET | 300 | 4.44 |
| 10:37 ET | 1169 | 4.4299 |
| 10:39 ET | 526 | 4.43 |
| 10:42 ET | 100 | 4.43 |
| 10:50 ET | 1072 | 4.46 |
| 10:51 ET | 100 | 4.46 |
| 10:57 ET | 100 | 4.46 |
| 11:02 ET | 200 | 4.45 |
| 11:06 ET | 400 | 4.46 |
| 11:24 ET | 314 | 4.46 |
| 11:31 ET | 100 | 4.47 |
| 11:33 ET | 100 | 4.465 |
| 11:36 ET | 532 | 4.48 |
| 11:42 ET | 100 | 4.4771 |
| 11:45 ET | 200 | 4.48 |
| 11:49 ET | 100 | 4.48 |
| 11:51 ET | 100 | 4.48 |
| 11:56 ET | 300 | 4.475 |
| 11:58 ET | 400 | 4.47 |
| 12:02 ET | 1361 | 4.44 |
| 12:03 ET | 200 | 4.44 |
| 12:18 ET | 11598 | 4.46 |
| 12:20 ET | 100 | 4.46 |
| 12:23 ET | 100 | 4.47 |
| 12:25 ET | 100 | 4.46 |
| 12:27 ET | 100 | 4.455 |
| 12:32 ET | 3226 | 4.45 |
| 12:34 ET | 600 | 4.445 |
| 12:36 ET | 100 | 4.445 |
| 12:38 ET | 10792 | 4.46 |
| 12:39 ET | 956 | 4.45 |
| 12:41 ET | 800 | 4.45 |
| 12:43 ET | 345 | 4.445 |
| 12:45 ET | 500 | 4.445 |
| 12:48 ET | 800 | 4.445 |
| 12:50 ET | 522 | 4.445 |
| 12:52 ET | 2300 | 4.45 |
| 12:54 ET | 100 | 4.45 |
| 12:56 ET | 300 | 4.45 |
| 01:01 ET | 100 | 4.45 |
| 01:06 ET | 400 | 4.46 |
| 01:10 ET | 100 | 4.451 |
| 01:14 ET | 100 | 4.455 |
| 01:24 ET | 100 | 4.46 |
| 01:42 ET | 305 | 4.46 |
| 01:44 ET | 300 | 4.475 |
| 01:53 ET | 100 | 4.48 |
| 02:00 ET | 2741 | 4.49 |
| 02:04 ET | 200 | 4.48 |
| 02:15 ET | 200 | 4.47 |
| 02:40 ET | 337 | 4.47 |
| 02:45 ET | 200 | 4.475 |
| 02:54 ET | 200 | 4.47 |
| 03:02 ET | 300 | 4.47 |
| 03:05 ET | 646 | 4.485 |
| 03:07 ET | 1183 | 4.495 |
| 03:09 ET | 7636 | 4.475 |
| 03:18 ET | 100 | 4.47 |
| 03:20 ET | 100 | 4.475 |
| 03:27 ET | 100 | 4.475 |
| 03:30 ET | 600 | 4.47 |
| 03:32 ET | 200 | 4.465 |
| 03:38 ET | 100 | 4.47 |
| 03:39 ET | 100 | 4.465 |
| 03:41 ET | 1200 | 4.465 |
| 03:43 ET | 2500 | 4.46 |
| 03:45 ET | 1467 | 4.47 |
| 03:48 ET | 100 | 4.475 |
| 03:50 ET | 200 | 4.48 |
| 03:52 ET | 725 | 4.48 |
| 03:54 ET | 100 | 4.48 |
| 03:56 ET | 4222 | 4.48 |
| 03:57 ET | 12039 | 4.49 |
| 03:59 ET | 4608 | 4.49 |
Jul 2, 2024
DJ Inozyme Pharma Price Target Maintained With a $14.00/Share by HC Wainwright & Co., from 10:47AM ET on Tuesday Jul 02, 2024 by Dow Jones
10:47AM ET on Tuesday Jul 02, 2024 by Dow JonesDJ Inozyme Pharma Gets FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency, from 8:40AM ET on Tuesday Jul 02, 2024 by Dow Jones
8:40AM ET on Tuesday Jul 02, 2024 by Dow JonesInozyme Pharma Announces FDA Fast Track Designation for INZ-701 in ABCC6 Deficiency, from 8:30AM ET on Tuesday Jul 02, 2024 by Dow Jones
8:30AM ET on Tuesday Jul 02, 2024 by Dow Jones
Jun 21, 2024
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Inozyme Pharma Inc | 277.7M | -3.3x | --- |
Atea Pharmaceuticals Inc | 276.3M | -1.7x | --- |
Nautilus Biotechnology Inc | 284.4M | -4.3x | --- |
ALX Oncology Holdings Inc | 291.8M | -1.5x | --- |
Black Diamond Therapeutics Inc | 249.8M | -2.6x | --- |
Zentalis Pharmaceuticals Inc | 247.1M | -1.1x | --- |
Company Information
Inozyme Pharma, Inc. is a clinical-stage rare disease biopharmaceutical company. The Company is focused on developing novel therapeutics for the treatment of diseases impacting the vasculature, soft tissue and skeleton. The Company is also focused on developing a novel therapy to treat the rare genetic diseases of Ectonucleotide Pyrophosphatase/Phosphodiesterase 1 (ENPP1) and ATP-Binding Cassette in the C6 family (ABCC6) Deficiencies. The Company’s lead product candidate, INZ-701, is a soluble, recombinant, genetically engineered, fusion protein that is designed to cleave extracellular adenosine triphosphate (ATP) to generate plasma pyrophosphate (PPi) and adenosine monophosphate (AMP), which can be processed to phosphate and adenosine. Its INZ-701 is in clinical development for the treatment of ENPP1 Deficiency, ABCC6 Deficiency and calciphylaxis.
Contact Information
- Headquarters
- 321 SUMMER STREET, SUITE 400BOSTON, MA, United States 02210
- Phone
- 857-330-4340
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Douglas Treco
- Chief Financial Officer, Corporate Secretary
- Sanjay Subramanian
- Chief Operations Officer
- Matthew Winton
- Director
- Axel Bolte
- Independent Director
- Sarah Bhagat
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $277.7M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 61.9M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.52 |
EPS | $-1.37 |
Book Value | $2.27 |
P/E Ratio | -3.3x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
